Enbrel, Prolia Suffer FDA’s Combination Punch On Device Components
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen did not follow proper procedures when it switched from one Enbrel vial adapter to another, FDA says, a change that led to an uptick in product complaints.